Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

Adicet Bio ( (ACET)) has issued an update. On December 19, 2025, Adicet Bio’s shareholders approved, and its board subsequently set, a 1-for-16 reverse stock split of the company’s common stock, which ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...

Shares of Mustang Bio (NASDAQ:MBIO) rocketed 580% in afternoon trading Monday after the biotech company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment ...

Q32 Bio on Monday sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ: AKBA). ADX-097, the lead product candidate from Q32 Bio’s tissue-targeted complement inhibitor ...

Investing.com -- Upstream Bio (NASDAQ:UPB) stock fell 23% after the company reported mixed results from its Phase 2 VALIANT trial of verekitug for severe asthma treatment.

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...